Identification of a battery of tests for drug candidate evaluation in the SMNΔ7 neonate model of spinal muscular atrophy

Experimental Neurology

Volumn 212, Issue 1, 2008, Pages 29-43

  El Khodor, Bassem F ^a   Edgar, Nicole ^a   Chen, Angela ^a   Winberg, Margaret L ^b   Joyce, Cynthia ^b   Brunner, Daniela ^a   Suárez Fariñas, Mayte ^c   Heyes, Melvyn P ^a  

^a PSYCHOGENICS INC   (United States)

^b Spinal Muscular Atrophy Foundation   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Drug screening; Moderate throughput; Motor neuron disease; Mouse genetic model; Neonate; Novel motor test; Phenotyping; Preclinical development; Tube test

Indexed keywords

SURVIVAL MOTOR NEURON PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; CONTROLLED STUDY; DRUG SCREENING; FEMALE; GEOTROPISM; HEREDITARY SPINAL MUSCULAR ATROPHY; INTERMETHOD COMPARISON; MALE; MOTOR PERFORMANCE; MOUSE; NEWBORN; NONHUMAN; POWER ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RIGHTING REFLEX; SURVIVAL; TUBE TEST; WELLBEING;

ANIMALS; ANIMALS, NEWBORN; BODY WEIGHT; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOVEMENT DISORDERS; NERVE TISSUE PROTEINS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; RNA-BINDING PROTEINS; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 44649093889     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.02.025     Document Type: Article

References (34)

1. Andreassi C., Zoli A., Riccio A., Scuderi F., Lombardi L., Altomonte L., and Eboli M.L. Anticardiolipin antibodies in patients with primary antiphospholipid syndrome: a correlation between IgG titre and antibody-induced cell dysfunctions in neuronal cell cultures. Clin. Rheumatol. 20 (2001) 314-318
2. Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., Villanova M., Bertini E., Pini A., Neri G., and Brahe C. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 12 (2004) 59-65
3. Avila A.M., Burnett B.G., Taye A.A., Gabanella F., Knight M.A., Hartenstein P., Cizman Z., Di Prospero N.A., Pellizzoni L., Fischbeck K.H., and Sumner C.J. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117 (2007) 659-671
4. Azzouz M., Le T., Ralph G.S., Walmsley L., Monani U.R., Lee D.C., Wilkes F., Mitrophanous K.A., Kingsman S.M., Burghes A.H., and Mazarakis N.D. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J. Clin. Invest. 114 (2004) 1726-1731
5. Barrett A.C., Negus S.S., Mello N.K., and Caine S.B. Effect of GABA agonists and GABA-A receptor modulators on cocaine- and food-maintained responding and cocaine discrimination in rats. J. Pharmacol. Exp. Ther. 315 (2005) 858-871
6. Brahe C., Vitali T., Tiziano F.D., Angelozzi C., Pinto A.M., Borgo F., Moscato U., Bertini E., Mercuri E., and Neri G. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 13 (2005) 256-259
7. Brichta L., Hofmann Y., Hahnen E., Siebzehnrubl F.A., Raschke H., Blumcke I., Eyupoglu I.Y., and Wirth B. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 12 (2003) 2481-2489
8. Butchbach M.E., Edwards J.D., and Burghes A.H. Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol. Dis. 27 (2007) 207-219
9. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. (1988), Academic Press, New York
10. Duchen L.W., Strich S.J., and Falconer D.S. Clinical and pathological studies of an hereditary neuropathy in mice (dystonia musculorum). Brain 87 (1964) 367-378
11. El-Khodor B.F., and Boksa P. Long-term reciprocal changes in dopamine levels in prefrontal cortex versus nucleus accumbens in rats born by caesarean section compared to vaginal birth. Exp. Neurol. 145 (1997) 118-129
12. Fruen B.R., Mickelson J.R., and Louis C.F. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol. Chem. 272 (1997) 26965-26971
13. Germinario E., Esposito A., Megighian A., Midrio M., Betto R., and Danieli-Betto D. Effects of modulators of sarcoplasmic Ca2+ release on the development of skeletal muscle fatigue. J. Appl. Physiol. 96 (2004) 645-649
14. Grondard C., Biondi O., Armand A.S., Lecolle S., Della Gaspera B., Pariset C., Li H., Gallien C.L., Vidal P.P., Chanoine C., and Charbonnier F. Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J. Neurosci. 25 (2005) 7615-7622
15. Hayashi M., Araki S., Arai N., Kumada S., Itoh M., Tamagawa K., Oda M., and Morimatsu Y. Oxidative stress and disturbed glutamate transport in spinal muscular atrophy. Brain Dev. 24 (2002) 770-775
16. Hirtz D., Iannaccone S., Heemskerk J., Gwinn-Hardy K., Moxley III R., and Rowland L.P. Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology 65 (2005) 1352-1357
17. Hsieh-Li H.M., Chang J.G., Jong Y.J., Wu M.H., Wang N.M., Tsai C.H., and Li H. A mouse model for spinal muscular atrophy. Nat. Genet. 24 (2000) 66-70
18. Jablonka S., Schrank B., Kralewski M., Rossoll W., and Sendtner M. Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. Hum. Mol. Genet. 9 (2000) 341-346
19. Jarecki J., Chen X., Bernardino A., Coovert D.D., Whitney M., Burghes A., Stack J., and Pollok B.A. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet. 14 (2005) 2003-2018
20. Kreider J.C., and Blumberg M.S. Geotaxis and beyond: commentary on Motz and Alberts (2005). Neurotoxicol. Teratol. 27 (2005) 535-537 author reply 543-534
21. Le T.T., Pham L.T., Butchbach M.E., Zhang H.L., Monani U.R., Coovert D.D., Gavrilina T.O., Xing L., Bassell G.J., and Burghes A.H. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14 (2005) 845-857
22. Lefebvre S., Burglen L., Reboullet S., Clermont O., Burlet P., Viollet L., Benichou B., Cruaud C., Millasseau P., Zeviani M., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80 (1995) 155-165
23. Lesbordes J.C., Cifuentes-Diaz C., Miroglio A., Joshi V., Bordet T., Kahn A., and Melki J. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 12 (2003) 1233-1239
24. Lunn M.R., Root D.E., Martino A.M., Flaherty S.P., Kelley B.P., Coovert D.D., Burghes A.H., Man N.T., Morris G.E., Zhou J., Androphy E.J., Sumner C.J., and Stockwell B.R. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem. Biol. 11 (2004) 1489-1493
25. McManamny P., Chy H.S., Finkelstein D.I., Craythorn R.G., Crack P.J., Kola I., Cheema S.S., Horne M.K., Wreford N.G., O'Bryan M.K., De Kretser D.M., and Morrison J.R. A mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 11 (2002) 2103-2111
26. Mercuri E., Bertini E., Messina S., Pelliccioni M., D'Amico A., Colitto F., Mirabella M., Tiziano F.D., Vitali T., Angelozzi C., Kinali M., Main M., and Brahe C. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord. 14 (2004) 130-135
27. Monani U.R., Sendtner M., Coovert D.D., Parsons D.W., Andreassi C., Le T.T., Jablonka S., Schrank B., Rossol W., Prior T.W., Morris G.E., and Burghes A.H. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9 (2000) 333-339
28. Mounsey J.P., Mistry D.J., Ai C.W., Reddy S., and Moorman J.R. Skeletal muscle sodium channel gating in mice deficient in myotonic dystrophy protein kinase. Hum. Mol. Genet. 9 (2000) 2313-2320
29. Riessland M., Brichta L., Hahnen E., and Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. 120 (2006) 101-110
30. Schrank B., Gotz R., Gunnersen J.M., Ure J.M., Toyka K.V., Smith A.G., and Sendtner M. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9920-9925
31. Singh N.K., Singh N.N., Androphy E.J., and Singh R.N. Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 26 (2006) 1333-1346
32. Sumner C.J., Huynh T.N., Markowitz J.A., Perhac J.S., Hill B., Coovert D.D., Schussler K., Chen X., Jarecki J., Burghes A.H., Taylor J.P., and Fischbeck K.H. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54 (2003) 647-654
33. Tamura N., Doolittle L.K., Hammer R.E., Shelton J.M., Richardson J.A., and Garbers D.L. Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17300-17305
34. Wirth B., Brichta L., Schrank B., Lochmuller H., Blick S., Baasner A., and Heller R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum. Genet. 119 (2006) 422-428